POST Online Media Lite Edition



 

Immune announces new operational leadership team

Staff writer |
Herzliya, Israel - April 3, 2014, Herzliya, Israel - Immune Pharmaceuticals Inc. announced the addition of Elliott Goldstein as chief medical officer and Eugene Williams as chief operating officer.




Dr. Goldstein brings a unique track record in the clinical, regulatory and commercial development of new pharmaceuticals. Dr. Goldstein began his career with Sandoz Pharmaceuticals (now Novartis), a fourteen-year period on drug development in France, Basel, Switzerland Global Headquarters, including as Head of Clinical R&D in the United States.

He subsequently held positions as SVP of Strategic Product Development at SmithKline Beecham (now GSK), CEO of British Biotech (Oxford, UK), Chief Operating Officer and Chief Medical Officer of Maxygen, and President and CMO of a startup biotech devoted to development of biosimilar monoclonal antibodies.

Dr. Goldstein holds an M.D. from the University Aix-Marseille II, Marseille, France, and a B.Sc. from McGill University, Montreal.

Mr. Williams is a former SVP at Genzyme, with senior roles integrating commercialization, drug development, and deal making. He is also an entrepreneur, as the founder and director of Adheris, which became the largest company in the patient adherence area. He was previously a strategy consultant at Bain and Corporate Decisions Inc. (a Bain Spin off, now part of Oliver Wyman), where he was co-Head of Healthcare and spent extensive time on speeding and improving the drug development process and on commercialization strategies.

 LATEST MOVES FROM Israel 

Nano Dimension appoints Miri Naveh to board
Teva says CFO Michael McClellan will step down
MaxQ AI announces Tom Neufelder as chief technology officer
SodaStream appoints Bryan Welsh as general manager of SodaStream USA
Protalix BioTherapeutic appoints David Granot to board

What to read next

Dyadic strengthens European leadership team
Immune Design appoints Susan Kelley to board of directors
G. John Mohr joins Immune as SVP, business development